CN102266463B - Application of compound Chinese medicine - Google Patents
Application of compound Chinese medicine Download PDFInfo
- Publication number
- CN102266463B CN102266463B CN 201110207399 CN201110207399A CN102266463B CN 102266463 B CN102266463 B CN 102266463B CN 201110207399 CN201110207399 CN 201110207399 CN 201110207399 A CN201110207399 A CN 201110207399A CN 102266463 B CN102266463 B CN 102266463B
- Authority
- CN
- China
- Prior art keywords
- parts
- rat
- chinese medicine
- radix
- compound chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 17
- 241000218176 Corydalis Species 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 210000005075 mammary gland Anatomy 0.000 abstract description 30
- 238000011160 research Methods 0.000 abstract description 12
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract description 2
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 47
- 210000000481 breast Anatomy 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 16
- 210000002445 nipple Anatomy 0.000 description 14
- 206010020718 hyperplasia Diseases 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 238000007689 inspection Methods 0.000 description 10
- 206010006298 Breast pain Diseases 0.000 description 9
- 208000006662 Mastodynia Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000011552 rat model Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical group C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010022998 Irritability Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229950002007 estradiol benzoate Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 206010006223 Breast discharge Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000002879 macerating effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000196422 Musculus lateralis Species 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001755 duct epithelial cell Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to application of a compound Chinese medicine, and relates to application of a compound Chinese medicine to the preparation of medicaments for treating proliferation of mammary gland. The compound Chinese medicine consists of the following components in part by weight: 100 to 500 parts of Chinese angelica, 50 to 400 parts of tree peony bark, 50 to 400 parts of red paeony root, 50 to 400 parts of bupleurum, 50 to 400 parts of peach seed, 50 to 400 parts of tangerine peel, 100 to 500 parts of nutgrass galingale rhizome, 50 to 500 parts of motherwort herb, 30 to 250 parts of chaff flower root, 50 to 400 parts of white paeony root and 50 to 400 parts of yanhusuo. Clinical researches indicate that: the clinical cure rate of the compound Chinese medicine for treating the proliferation of mammary gland is 70.75 percent, the total effective rate is 92.45 percent, and the compound Chinese medicine does not have adverse reaction and abnormal phenomena.
Description
One, technical field
The present invention relates to a kind of new purposes of known substance, exactly is a kind of new purposes of herbal mixture.
Two, background technology
Cyclomastopathy claims again cystic hyperplasia of breast, is more common in 30～50 years old women, belongs to breast duct and lobule degeneration structurally and the variation of carrying out property.Be the cystic dilatation of conduit on the one hand, form the cyst that differs in size; That ductal epithelium has papillary hyperplasia in various degree on the other hand, in the lobule and the fibrous tissue around the lobule in various degree hypertrophy is also arranged.Its cause of disease is how relevant with ovarian dysfunction.
Primary disease belongs to the traditional Chinese medical science " nodules of the breast " category, claims again " breast chestnut ", " breast carcinoma ", " newborn painful abdominal mass ".
The treatment of relevant cyclomastopathy, doctor trained in Western medicine there is no definite medicine at present.The traditional Chinese medical science is thought, causes this pathogenetic reason, and is how unsuccessful by feelings will, depression of liver-QI, or by overabundant liver-fire, and diet raw food is condensed into expectorant, and phlegm-fire interweaves, knot and in bulk is to be nodules of the breast.Say just as " surgery is really annotated ": " nodules of the breast, tuberculosis of breast is hard, and it is large such as money to begin, and gradually large such as peach, such as ovum, color of the leather is as usual, meets coldly to have a pain, and is always cold by the cold physique drink, stagnation of QI phlegm retention in addition, inflow stomach warp is due to cannot not gathering loosely." in the treatment, " Yangke Xinde Ji, Experience Gained in Treating External Diseases " has cloud: " needn't control stomach, but treating the liver and swollen from disappearing ".
Three, summary of the invention
The present invention is in view of the clinical status that there is no at present active drug treatment cyclomastopathy, aim to provide the medicine that can effectively treat cyclomastopathy, technical problem to be solved is to select in known herbal mixture by pharmacology and clinical research to supply the active drug of clinical practice.
Discussion according to the traditional Chinese medical science " treating the liver swells from disappearing ", the applicant on July 14th, 2010 applied for that an application number is 201010229085.2, name is called the patent of invention (calling in the following text in front application) of " for the preparation of the medicine for the treatment of hysteromyoma ", in the herbal mixture compositions of this application, contain the Chinese medicine that Radix Bupleuri, Rhizoma Cyperi etc. have the depressed liver-energy dispersing and QI regulating mass-dissipating efficacy, therefore, the applicant has carried out pharmacological research and clinical research for cyclomastopathy to this herbal mixture in front application.
Herbal mixture in front application is comprised of following weight portion raw material:
Radix Angelicae Sinensis 100-500 Cortex Moutan 50-400 Radix Paeoniae Rubra 50-400 Radix Bupleuri 50-400 Semen Persicae 50-400 Pericarpium Citri Reticulatae 50-400
Rhizoma Cyperi 100-500 Herba Leonuri 50-500 Radix Achyranthis Bidentatae 30-250 Radix Paeoniae Alba 50-400 Rhizoma Corydalis 50-400.
Preferably:
Radix Angelicae Sinensis 380 Cortex Moutans 190 Radix Paeoniae Rubra 190 Radix Bupleuri 190 Semen Persicaes 190 Pericarpium Citri Reticulataes 190
Rhizoma Cyperi 380 Herba Leonuris 288 Radix Achyranthis Bidentataes 115 Radix Paeoniae Albas 190 Rhizoma Corydalis 190.
The preparation method of this herbal mixture:
Half of getting the Rhizoma Corydalis parts by weight is ground into fine powder, remain ten flavors such as half and Radix Angelicae Sinensis and be ground into coarse granule, add 6-12 times of water gaging warm macerating 2 hours, filter, filtrate is concentrated into the clear paste that relative density is 1.05-1.10, and drying is made the clear paste powder, again with above-mentioned Rhizoma Corydalis fine powder mixing, make tablet or capsule after adding the appropriate amount of auxiliary materials drying.
The Tablet and Capsula agent of processing claims Shuerjing sheet and Shuerjing capsule.In carrying out pharmacology and clinical research, use this trade name to show difference.
The purposes of this herbal mixture is exactly the application in preparation treatment cyclomastopathy medicine.
This herbal mixture is comprised of Radix Angelicae Sinensis, Cortex Moutan, Radix Paeoniae Rubra, Radix Bupleuri, Semen Persicae, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Radix Achyranthis Bidentatae, Herba Leonuri, Rhizoma Corydalis, the Radix Paeoniae Alba ten a herbs.Radix Bupleuri, Rhizoma Cyperi depressed liver-energy dispersing and QI regulating in the side are with the pent-up of soothing liver-QI gas.Radix Angelicae Sinensis, Radix Paeoniae, Cortex Moutan cooling blood and removing stasis, by theory of Chinese medical science, on can the fall apart caking of breast, the blood stasis in lower adjustable uterus.Assistant is with the Rhizoma Corydalis promoting the circulation of QI to relieve pain, the Pericarpium Citri Reticulatae happy stomach of being amusing, and Herba Leonuri blood stasis dispelling regulating menstruation, Radix Achyranthis Bidentatae leads down stasis.Full side's compatibility, dispersing liver-energy, the eliminating stagnation piece, Removing Blood Stasis is led stasis of blood row, so this herbal mixture not only can be used for the treatment of menoxenia due to the stagnation of QI due to depression of the liver, dysmenorrhea etc., also tackling irritability stasis card cyclomastopathy has therapeutical effect.Prove that through pharmacological research and clinical research this herbal mixture has significant therapeutic effect to cyclomastopathy.
Four, description of drawings
Accompanying drawing is depicted as hyperplasia of mammary gland model rat mammary gland tectology and changes light microscopic figure.
The blank group of Fig. 1 rat mammary gland pathomorphology inspection figure;
Fig. 2 model group rat mammary gland pathomorphology inspection figure;
Fig. 3 model group rat mammary gland pathomorphology inspection figure;
Fig. 4 tamoxifen group rat mammary gland pathomorphology inspection figure;
Fig. 5 RUPIXIAO group rat mammary gland pathomorphology inspection figure;
Fig. 6 high dose Shuerjing sheet group rat mammary gland pathomorphology inspection figure;
Dosage Shuerjing sheet group rat mammary gland pathomorphology inspection figure among Fig. 7;
Fig. 8 low dosage Shuerjing sheet group rat mammary gland pathomorphology inspection figure.
Five, the specific embodiment
(1) preparation of this herbal mixture
Prescription is: Radix Angelicae Sinensis 380g, Cortex Moutan 190g, Radix Paeoniae Rubra 190g, Radix Bupleuri 190g, Semen Persicae 190g, Pericarpium Citri Reticulatae 190g, Rhizoma Cyperi 380g, Radix Achyranthis Bidentatae 115g, Herba Leonuri 288g, Rhizoma Corydalis 190g, Radix Paeoniae Alba 190g;
Method for making: above ten simply, gets Rhizoma Corydalis 95g, is ground into fine powder, ten flavors such as remainder and Radix Angelicae Sinensis are ground into coarse granule, add 10 times of water gaging warm macerating (95 ± 5 ℃) 2 hours, filter, filtrate is concentrated into the clear paste that relative density is 1.05-110 (50-60 ℃), spray drying is made the clear paste powder, with above-mentioned fine powder mixing, make 1000 seed lac wafers or add an amount of magnesium stearate after adding an amount of dextrin and starch drying, tabletting, film coating is made 1000; Wherein every heavy 0.5 in tablet restrains, every 0.5 gram of capsule;
Usage and dosage: oral; 2 in tablet one time, 2 of capsules one time.
The applicant entrusts Anhui Chinese Medicine College herbal pharmacology chamber and Affiliated Hospital to carry out respectively pharmacological research and clinical research, and the result is as follows:
(2) to the pharmacological research of hyperplasia of mammary gland model rat
1 material
1.1 laboratory animal
The SD rat, weight 250 ± 20g, female; Provided by the Anhui length Pharmaceutical Technology Co., Ltd that borders on the river.
1.2 pharmaceutical agent
The Shuerjing sheet, the modern more pharmaceutical Co. Ltd's (lot number: 101001) in Hefei; Tamoxifen, Yangzijiang Pharmaceutical Group Co., Ltd's (lot number: 10091011); BUPIXIAO PIAN, the good nurse's Pharmaceutical in Liaoning Co., Ltd (lot number: 091221); Progesterone injection, Zhejiang Province XianJu Pharmacy stock Co., Ltd's (lot number: 101003); Estradiol benzoate injection, Tianjin gold credit aminoacid company limited (lot number: 1007041); Estradiol (E
2), progesterone (P) radioimmunoassay kit, Tianjin Xin Wan bio tech ltd (lot number: 100323).
1.3 instrument and equipment
YDA-IV type blood viscometer, Beijing Hong Run reaches the development in science and technology company limited; Extracorporeal thrombosis forming device; BS-110S precise electronic balance, Beijing Sai Duolisi balance company limited; The TDL-16C table model high speed centrifuge, Anting Scientific Instrument Factory, Shanghai; Slide gauge.
2 methods
2.1 the foundation of cyclomastopathy rat model
Adopt the method for estrogen and progestogen load to set up the cyclomastopathy rat model.Injection estradiol benzoate in the rat hindlimb musculus lateralis externi, 0.5mg/kg injects 25d continuously.Inject subsequently Progesterone, 0.5mg/kg, continuously 5d.
2.2 grouping and administration
After feeding 1w, 70 rat adaptabilities are divided at random: 10 of blank groups, 60 of model group.The model group rat is set up the cyclomastopathy animal model as stated above, and blank group rat is injected isopyknic normal saline.After modeling finishes, 60 rat models are divided into by breast diameter: model group, RUPIXIAO group (0.81g/kg), tamoxifen group (0.0056g/kg), Shuerjing high (1.12g/kg), in (0.56g/kg), low (0.28g/kg) dosage group, every group 10, each group beginning gastric infusion, the administration volume is 10ml/kg, and blank group and model group give isopyknic 0.5%CMC-Na solution.Successive administration 30d, every 5d weighing the weight of animals 1 time is adjusted the administration volume according to the weight of animals.
3 index observings and detection method
3.1 the animal general state is observed
Observe outward appearance, hair color, spirit, the activity of animal every day, every 5d weighs 1 time, observe the variation of the weight of animals and adjust dosage, and with precision vernier callipers after modeling, 2 stages are accurately measured about the 2nd pair two breast diameter of rat and height of nipples after the administration, to observe the model variation tendency.
3.2 breast diameter, height of nipples
Measure breast diameter and height of nipples after modeling finishes 1 time, measure breast diameter and height of nipples after administration finishes 1 time, more than all accurately measure about the 2nd pair two breast diameter of rat and height of nipples with slide gauge.
3.3 hemorheology detects
3.3.1 whole blood and plasma viscosity are measured
Administration 30d, after the last administration, water 16h is can't help in fasting, 3.5% chloral hydrate anesthesia (ip, 10ml/kg), abdominal aortic blood 1ml, place the anticoagulant heparin pipe, with blood viscosity instrument measure height cut (120/s), in cut (70/s), low whole blood viscosity of cutting under (30/s).Other gets 3ml blood and places the EDTA-2K anticoagulant tube, 4000rpm, and centrifugal 20min gets supernatant, measures plasma viscosity with blood viscosity instrument.
3.3.2 the mensuration of clotting time, thrombosis length and packed cell volume
Abdominal aortic blood drips rapidly some blood on microscope slide, begins to clock, and every 15 seconds, instigates once with No. 6 syringe needle, and record is clotting time from dripping blood to the blood streak time occurring.Push away at once 1ml blood in thrombus tube, measure thrombotic length at the external thrombus instrument.Other gets blood 1ml and places the EDTA-2K anticoagulant tube, carefully enters Hematocrit tube with puncture needle, leaves standstill 1h, 4000rpm, and centrifugal 20min measures the packed cell volume value.
3.4 estradiol (E in the serum
2), the assay of progesterone (P)
Leave standstill 1h after getting blood, 3500rpm, centrifugal 20min, separation of serum-20 ℃ preservation.Radioimmunology detects E in the serum
2, P content, concrete operations are undertaken by the test kit description.
3.5 Basic Research on Breast Pathology is observed
After each organizes rat execution, cut the mammary gland of the 2nd pair of breast of rat, fix with 10% formaldehyde, paraffin section, HE dyeing is observed its tectology and is changed under the light microscopic.
4 statistical methods
Experimental data is used
SPSS12.0 for windows software processing system statistical analysis is adopted in expression, and group difference relatively adopts one factor analysis of variance, and P＜0.05 shows to have significant difference.
5 results
5.1 the general state of animal is observed
During the model copy, the minimizing of searching for food of modeling group, body weight increases slowly, enters the administration after date, and the increase of model group body weight recovers normally gradually, and the respective stage body weight increase difference of administration group and blank group is not remarkable.This experimental model group and matched group compare, and breast is whole obviously to be increased, and nipple is holded up, and is more solid, hyperemia, and papilla diameter increases, and loses weight; Shuerjing sheet group rat and model group compare, and papilla diameter and highly significant reduce, and mammary gland weight obviously alleviates, and it is less to lose weight.In experiment gavage process, the rats death phenomenon occurs, enter pulmonary by medicinal liquid and cause rats death.
5.2 modeling result
After the experiment beginning, with precision vernier callipers before modeling, after the modeling, three phases is accurately measured about the 2nd pair two breast diameter of rat and height of nipples after the administration, rat is behind the injection estrogen and progestogen, the rat nipple occurs red and swollen or increases, enlargement appears in breast, increases (P＜0.001) with the blank group than equal significance and shows model copy success (seeing Table 1).
About the 2nd pair two breast diameter of rat and height of nipples after table 1 modeling
Annotate: with blank group ratio,
▲ ▲ ▲P＜0.001
5.3 the Shuerjing sheet is on the impact of cyclomastopathy rat
5.3.1 the Shuerjing sheet is on the impact of breast diameter, height of nipples
Rat is after modeling, and model group all has significant difference (P＜0.001) with the blank group than breast diameter and height of nipples; Each administration group has significant therapeutic effect to unusual increase of cyclomastopathy rat breast diameter, all has significant difference (P＜0.05, P＜0.01) with the model group ratio; Each administration group all can reduce the abnormal milk grease head highness, and wherein low, middle dosage group has notable difference (P＜0.05) with the model group ratio, and the high dose group height of nipples has reduction trend, but no difference of science of statistics (seeing Table 2).
Table 2 Shuerjing sheet is on the impact of rat second on left and right sides breast diameter and height of nipples
Annotate: with blank group ratio,
▲P＜0.05,
▲ ▲P＜0.01,
▲ ▲ ▲P＜0.001; With the model group ratio,
★P＜0.05,
★ ★P＜0.01
5.3.2 the impact on whole blood viscosity and plasma viscosity
Model group rat whole blood viscosity significantly raise (P＜0.05); Each administration group whole blood and plasma viscosity all make moderate progress, wherein comparatively remarkable (P＜0.05) (the seeing Table 3) of Shuerjing high and low dose group.
Table 3 Shuerjing sheet is on the impact of hyperplasia of mammary gland model rat whole blood viscosity and plasma viscosity
Annotate: with blank group ratio,
▲P＜0.05, with the model group ratio,
★P＜0.05
5.3.3 the impact on clotting time
Model group rat clotting time shortens to some extent with blank group ratio, but no difference of science of statistics; Each administration group cruor time extending, but no difference of science of statistics (seeing Table 4).
Table 4 Shuerjing sheet is on the impact of hyperplasia of mammary gland model rat clotting time
5.3.4 the impact on thrombosis length
Model group rat suppository length obviously increases (P＜0.05) with blank group ratio; Each administration group thrombosis length shortens to some extent, and the Shuerjing high dose group is (P＜0.05) (seeing Table 5) comparatively significantly.
Table 5 Shuerjing sheet is on the impact of hyperplasia of mammary gland model rat suppository length
Annotate: with blank group ratio,
▲P＜0.05; With the model group ratio,
★P＜0.05
5.3.5 the impact on packed cell volume
Model group Rat Erythrocytes hematocrit is compared remarkable reduction (P＜0.001) with the blank group; Each administration group packed cell volume raises to some extent, but not statistically significant (seeing Table 6).
Table 6 Shuerjing sheet is on the impact of hyperplasia of mammary gland model Rat Erythrocytes hematocrit
Annotate: with blank group ratio,
▲ ▲ ▲P＜0.001; With the model group ratio,
★P＜0.05
5.3.6 the Shuerjing sheet is to cyclomastopathy rat E
2, P content impact
Compare E in the model group rat blood serum with the blank group
2Significantly raise, P significantly reduces; Compare E in each administration group rat blood serum with model group
2Content decreases, P content raises to some extent, but equal not statistically significant (seeing Table 7).
Table 7 Shuerjing sheet is to cyclomastopathy rat blood serum E
2, P impact
Annotate: compare with model group,
▲P＜0.05
5.3.7 the Shuerjing sheet is on the pathological impact of cyclomastopathy rat mammary gland
Blank group rat mammary gland tissue pathological slice is observed and is all found no the cyclomastopathy symptom, and the lobules of mammary gland volume is little, and leaflet is few, and breast duct epithelial cell queueing discipline is in state resting stage; The obvious hypertrophy of the visible lobules of mammary gland of model group rat, lobule acinus number showed increased, the ductal epithelial cell number of plies increases, and cell arrangement is disorderly, is typical cyclomastopathy symptom.The cyclomastopathy symptom of the degree of cyclomastopathy and model control group comparison rat all has and alleviates in various degree and alleviate after the Shuerjing Drug therapy, comparatively obvious with the Shuerjing high and low dose, prompting Shuerjing sheet has certain therapeutical effect (Fig. 1) for cyclomastopathy.
6 conclusions
Experimental result shows, adopts estradiol benzoate and Progesterone outer rim intramuscular injection successfully to copy the cyclomastopathy rat model; After rat model gavages the Shuerjing sheet, the Shuerjing sheet all obviously improves the unusual increase of rat model breast diameter and height of nipples, improve the rat model hemorheological property, pathological examination shows that the Shuerjing sheet has some improvement to cyclomastopathy, mammary gland alveolus chamber diameter and glandular cell height reduce, and lobules of mammary gland hamartoplasia pathological changes alleviates to some extent.Show that the Shuerjing sheet has certain therapeutical effect to the cyclomastopathy rat, the performance of this effect may to improve hemorheological property relevant with medicine.
(3) to the clinical research of caused by hepatic stagnation qi stagnation cyclomastopathy
1), physical data
In August, 2009～2010 year July, observe altogether case 106, be married women.Wherein, 22 years old of age minimum, maximum 43 years old, 36.7 years old mean age.The shortest 8 months of the course of disease, the longest 6 years, average course of disease 3 years 4 months.All patients all meets cyclomastopathy irritability stasis disease through clinical diagnosis.
Among the 106 routine patients, light-duty patient's 15 examples account for 14.15%; Medium-sized patient's 62 examples account for 58.49%; Heavy patient's 29 examples account for 27.36%.Took medicine the shortest 30 days, the longest 57 days, on average took medicine 46 days.
2), Therapeutic Method
Oral administration, 2 times on the 1st, 1 time 2,30 days is 1 course for the treatment of.
3), diagnostic criteria
Diagnosis basis: " guideline of clinical investigations of new Chinese medicine treatment cystic hyperplasia of breast " Ministry of Health of the People's Republic of China developed and published in 1997
. the Western medicine diagnose standard
(1) mastalgia, generally not serious.Mostly be bilateral, also can be one-sided, for dull pain, distending pain, dull pain or twinge, alter pain, pendant pain, burning pain, normal companion touches a tender spot.Can increase the weight of before the menstruation or during anxious state of mind.
(2) lump in breast: mostly be bilateral, in the majority with outside upper quadrant.
Single lump: capsule, clear-cut margin, mobility is large.
Most lumps: multiple capsule tuberosity, can involve two breasts or full milk, obscure boundary.
The mammary gland sector tuberosity: tuberosity is pressed the latex dust system and is distributed, and subtriangular, the base is positioned at the mammary gland edge, and not of uniform size for irregular agglomerate, rope strip, graininess, soft or hard does not wait, and obscure boundary is with the skin adhesion.
(3) nipple discharge: discharge or when touching by certain latex dust system voluntarily, can cause nipple discharge, mostly be yellow serosity.
(4) x-ray diagnosis: increase in density, but inhomogeneous, obscure boundary.
(5) far infrared inspection: be cloud and mist lump shadow, obscure boundary.
(6) the molybdenum target breast is taken the photograph sheet: the fuzzy shade that visible density thickens, number is indefinite, if the extensive person's breast density of pathological changes evenly increases. and extent of disease is little, then the irregular girder in visible edge.Cystic hyperplasia is the shade of the neat in edge of circular or irregular arc, and a lucent area is arranged on every side.
(7) pathologic finding: typical cystic hyperplasia of breast sexually transmitted disease (STD) reason changes.
. Chinese medical discrimination
Take mastalgia as main, mostly be distending pain, alter pain, the growth and decline with menstrual cycle and emotion changes.The lump soft or hard does not wait in the breast, companion's breast side of body feeling of distension and oppression, and irritated irritability, body of the tongue is thin white, stringy pulse.
. the classification of state of an illness weight
Light-duty: mastalgia is dull pain, alter pain, and one-sided or bilateral lump in breast is single little lump, or is graininess and scope is little, or is streak thing, and is softer, is confined to a quadrant.
Medium-sized: mastalgia is dull pain or alters pain and tenderness is arranged that distending pain is obvious, and lump is larger, or in the form of sheets, plate-like, involve two breasts, but scope is at two quadrants.
Heavy: mastalgia is touched a tender spot obviously for pendant pain or twinge, and lump is large, and multiple capsule tuberosity involves two breasts, and scope is at two more than the quadrant.
4), test case standard
. include the case standard in
Meet primary disease diagnostic criteria and Standards of Chinese Medical Syndrome Differentiation person, can include the test case in.
. the Excluded cases standard
(1) merges breast tumor person.
(2) age is at under-18s or more than 50 years old, gestation or women breast-feeding their children, allergic constitution or those who are allergic to this drug.
(3) merge the serious primary disease such as cardiovascular and cerebrovascular disease, liver, kidney and hemopoietic system, psychotic.
(4) do not meet inclusive criteria, not in accordance with regulations medication can't be judged curative effect, or data is not congruent affects the treatment or safety judgement person.
5), observation index
. safety observation
(1) general health check-up project.
(2) blood, urine, just routine examination.
(3) Electrocardioscopy.
(4) liver, kidney function test.
. health giving quality observation
(1) related symptoms and sign.
(2) the molybdenum target breast is taken the photograph the sheet inspection.
6), curative effect determinate standard
. clinical recovery: mastalgia and lump disappear.
. produce effects: mastalgia disappears, and heavy type becomes light-duty, and mammary gland tumor dwindles＞and 1/2.
. effectively: mastalgia disappears or alleviates, and heavy type becomes medium-sized, medium-sizedly becomes light-dutyly, and mammary gland tumor dwindles≤and 1/2.
. invalid: mastalgia does not alleviate or increases the weight of, and mammary gland tumor is not dwindled or increased on the contrary.
7), therapeutic outcome
106 routine patients, 41 examples of fully recovering account for 38.68%; Produce effects 34 examples account for 32.08%; Effective 23 examples account for 21.70%; Invalid 8 examples account for 7.55%; Clinical cure-remarkable-effectiveness rate 70.75%, total effective rate 92.45%.All patients is not found obvious adverse reaction and unusual through clinical and lab testing.
8), discuss
Shuerjing sheet side is comprised of Radix Angelicae Sinensis, Cortex Moutan, Radix Paeoniae Rubra, Radix Bupleuri, Semen Persicae, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Radix Achyranthis Bidentatae, Herba Leonuri, Rhizoma Corydalis, the Radix Paeoniae Alba ten a herbs.Radix Bupleuri, Rhizoma Cyperi depressed liver-energy dispersing and QI regulating in the side are with the pent-up of soothing liver-QI gas.Radix Angelicae Sinensis, Radix Paeoniae, Cortex Moutan cooling blood and removing stasis, on can the fall apart caking of breast, the blood stasis in lower adjustable uterus.Assistant is with the Rhizoma Corydalis promoting the circulation of QI to relieve pain, the Pericarpium Citri Reticulatae happy stomach of being amusing, and Herba Leonuri blood stasis dispelling regulating menstruation, Radix Achyranthis Bidentatae leads down stasis.Full side's compatibility, dispersing liver-energy, the eliminating stagnation piece, Removing Blood Stasis is led stasis of blood row, so not only can be used for the treatment of menoxenia due to the stagnation of QI due to depression of the liver, dysmenorrhea etc., simultaneously cyclomastopathy irritability stasis card is also had significant therapeutical effect.
Claims (2)
1. the purposes of a herbal mixture is characterized in that: the application of herbal mixture in preparation treatment cyclomastopathy medicine that is comprised of Radix Angelicae Sinensis 100-500, Cortex Moutan 50-400, Radix Paeoniae Rubra 50-400, Radix Bupleuri 50-400, Semen Persicae 50-400, Pericarpium Citri Reticulatae 50-400, Rhizoma Cyperi 100-500, Herba Leonuri 50-500, Radix Achyranthis Bidentatae 30-250, Radix Paeoniae Alba 50-400, the Rhizoma Corydalis 50-400 of following weight portion.
2. the purposes of herbal mixture according to claim 1 is characterized in that: the application of herbal mixture in preparation treatment cyclomastopathy medicine that is comprised of Radix Angelicae Sinensis 380, Cortex Moutan 190, Radix Paeoniae Rubra 190, Radix Bupleuri 190, Semen Persicae 190, Pericarpium Citri Reticulatae 190, Rhizoma Cyperi 380, Herba Leonuri 288, Radix Achyranthis Bidentatae 115, the Radix Paeoniae Alba 190, the Rhizoma Corydalis 190 of following weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110207399 CN102266463B (en) | 2011-07-22 | 2011-07-22 | Application of compound Chinese medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110207399 CN102266463B (en) | 2011-07-22 | 2011-07-22 | Application of compound Chinese medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102266463A CN102266463A (en) | 2011-12-07 |
| CN102266463B true CN102266463B (en) | 2013-04-17 |
Family
ID=45049044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110207399 Active CN102266463B (en) | 2011-07-22 | 2011-07-22 | Application of compound Chinese medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102266463B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263556B (en) * | 2013-06-03 | 2016-07-06 | 合肥今越制药有限公司 | A kind of purposes of herbal mixture |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1654070A (en) * | 2005-01-31 | 2005-08-17 | 刘小清 | Composite Chinese medicinal soft capsule for treating emmeniopathy and its preparing method |
| CN1742919A (en) * | 2005-09-23 | 2006-03-08 | 北京润德康医药技术有限公司 | Shuerjing Chinese medicine preparation and preparing method thereof |
| CN101897855A (en) * | 2010-07-14 | 2010-12-01 | 合肥今越制药有限公司 | Medicament for treating uterine myoma |
-
2011
- 2011-07-22 CN CN 201110207399 patent/CN102266463B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1654070A (en) * | 2005-01-31 | 2005-08-17 | 刘小清 | Composite Chinese medicinal soft capsule for treating emmeniopathy and its preparing method |
| CN1742919A (en) * | 2005-09-23 | 2006-03-08 | 北京润德康医药技术有限公司 | Shuerjing Chinese medicine preparation and preparing method thereof |
| CN101897855A (en) * | 2010-07-14 | 2010-12-01 | 合肥今越制药有限公司 | Medicament for treating uterine myoma |
Non-Patent Citations (2)
| Title |
|---|
| 安泽余.中医药治疗乳腺增生病临床研究进展.《河北中医》.2009,第31卷(第08期),1268-1270. * |
| 芦锰.乳腺增生病的中医药治疗概况.《河南中医学院学报》.2007,第22卷(第02期),83-85. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102266463A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009062338A1 (en) | A lactogenic chinese medicine for treatment and prevention of gynecopathy, methods of preparation and uses thereof | |
| CN106421633A (en) | Pharmaceutical composition for treating Hashimoto's thyroiditis and preparation method thereof | |
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN1692939B (en) | Compound traditional Chinese medicine for treating proliferation of mammary gland, and its preparation method | |
| CN102302567B (en) | Stagnation-removing and stasis-removing Chinese patent medicine | |
| CN105327069A (en) | Formulation, preparation method and application of liver soothing traditional Chinese herbal medicine composition | |
| CN102309651B (en) | New use of compound traditional Chinese medicine | |
| CN102908579B (en) | Traditional Chinese medicine preparation for treating gynecological diseases, liver diseases and prostatitis and preparation method of traditional Chinese medicine preparation | |
| CN102266463B (en) | Application of compound Chinese medicine | |
| CN103933430B (en) | Chronic hepatitis B medicine and preparation method thereof | |
| CN102641478B (en) | Oral medicament for treating hyperplasia of mammary glands | |
| CN111514241B (en) | Traditional Chinese medicine composition for treating female hyperplasia of mammary glands and preparation method thereof | |
| CN101664533A (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN104043042A (en) | Traditional Chinese medicine composition for treating hepatic calculus | |
| CN107812085A (en) | It is a kind of to treat the proliferation of mammary gland, the Chinese medicine composition and preparation method thereof of tubercle | |
| CN102861159A (en) | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof | |
| CN105902951A (en) | Traditional Chinese medicinal compound for treating osteosarcomas on basis of chemotherapeutic drugs | |
| CN105435134A (en) | Chinese herbal preparation for treating stomach cancer together with chemotherapeutic drugs | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN106266931A (en) | A kind of Chinese medicine composition treating gynecological tumor and preparation method thereof | |
| CN1318066C (en) | Medicine for treating dysmenorrhes and preparation thereof | |
| CN115581749B (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and preparation method thereof | |
| CN111135270A (en) | A Chinese medicinal composition for treating female hyperplasia of mammary glands due to stagnation of qi and stagnation of liver-qi and stagnation of phlegm and blood stasis | |
| CN103585583A (en) | Traditional Chinese medicine composition for treating hepatic calculus and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application of compound Chinese medicine Effective date of registration: 20190329 Granted publication date: 20130417 Pledgee: Merchants Bank of Hefei Economic Development Zone Branch Pledgor: HEFEI JINYUE PHARMACEUTICAL Co.,Ltd. Registration number: 2019340000166 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200713 Granted publication date: 20130417 Pledgee: Merchants Bank of Hefei Economic Development Zone Branch Pledgor: HEFEI JINYUE PHARMACEUTICAL Co.,Ltd. Registration number: 2019340000166 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Use of a compound Chinese medicine Effective date of registration: 20230116 Granted publication date: 20130417 Pledgee: Huishang Bank Co.,Ltd. Hefei Economic Development Zone sub branch Pledgor: HEFEI JINYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980030921 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20130417 Pledgee: Huishang Bank Co.,Ltd. Hefei Economic Development Zone sub branch Pledgor: HEFEI JINYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980030921 |